Clinical trial · Interventional
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma
NCT00308607CI-TRIAL-00002195completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab (Avastin) | Drug | Bevacizumab | ALIAS |
| dacarbazine | Drug | Dacarbazine | ALIAS |
| interferon-alfa-2a (Roferon-A) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Response rate according to RECIST criteria
- measure
- Progression-free survival
- measure
- Time to brain metastases
- measure
- Overall survival
Secondary outcomes (2)
- measure
- To evaluate safety of this combination after every two cycles
- measure
- Serum analysis of particular biochemical markers
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed malignant melanoma either locally progressing inoperable or metastatic * measurable/evaluable disease in accordance with RECIST criteria * WHO performance status 0-2 * normal organ function * signed written informed consent Exclusion Criteria: * unevaluable disease * major surgery within 28 days prior to day 0 * uncompleted radiotherapy * CNS metastases * serious non-healing wound or ulcer * bleeding diathesis or coagulopathy * uncontrolled hypertension * clinically significant cardiovascular disease * depression or psychosis, which needs medication * ongoing treatment with aspirin (\>325 mg/day) * pregnancy * any other serious or uncontrolled illness * previous chemotherapy for metastatic melanoma
References
Publications (0)
Data not yet available
No reference posted for this study.